Poor Outcome in High–Molecular Risk, Hydroxycarbamide Resistant/Intolerant ET Is Not Ameliorated by Ruxolitinib
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The Poor Outcome in High Molecular Risk, Hydroxycarbamide Resistant/Intolerant ET Is Not Ameliorated by Ruxolitinib
Blood 2019 Oct 02;[EPub Ahead of Print], JM O'Sullivan, A Hamblin, C Yap, S Fox, R Boucher, A Panchal, S Alimam, HM Dreau, K Howard, P Ware, NC Cross, MF McMullin, CN Harrison, AJ MeadFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.